Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16735513 | 0.90 | CCR2 (0.48) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL16735464 | 0.83 | CCR2 (0.48) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL9931338 | 0.81 | CCR2 (0.64) | CCR2MEN1KMT2APKM | |
| SCHEMBL16735474 | 0.78 | CCR2 (0.52) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL16735503 | 0.76 | CCR2 (0.48) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL16735481 | 0.76 | CCR2 (0.51) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL16735458 | 0.76 | CCR2 (0.51) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL16735455 | 0.75 | CCR2 (0.50) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL16735460 | 0.75 | CCR2 (0.50) | CCR2ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL19406113 | 0.74 | CCR2 (0.73) | CCR2MEN1KMT2ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | claimed |
| EP-2651901-B1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-05-27 | — | — | EP | claimed |
| US-8580779-B2 | 1,2-bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CCR2 2/4885ALDH1A1 2379/4885MAPT 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.